Skip to main content
← All trials
Oesophageal Squamous Cell CarcinomaCancerBiologicalDrugPhase 1, Phase 2

What this study is

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.

The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.

What's being tested

  • I-DXd

    Intervention · BIOLOGICAL

    IV Infusion

  • Rescue Medication

    Intervention · DRUG

    Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid, administered per approved product label

Study details

Official title
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
Sponsor
Merck Sharp & Dohme LLC
Conditions
Oesophageal Squamous Cell Carcinoma
Enrolling
60 people
Starts
2026-03-27
Est. completion
2028-06-12
Design
Open-label, single group, Phase 1, Phase 2
Record
View on ClinicalTrials.gov ↗